复星医药(02196) - 2025 Q1 - 电话会议演示

Investor Presentation 1Q25 Report Prepared in accordance with China Accounting Standards Contents 1 Performance Highlights and Financial Review 2 Innovation and Internationalization 3 Pharmaceutical 1Q25 Financial Review (1/2) Revenue RMB 9,420 million (-7.26%YoY) R&D Expense RMB 737 million (-11.10%YoY) Net Operating Cash Flow RMB 1,056 million (+15.08%YoY) 4 Med Tech 5 Healthcare Services 6 Appendix Performance Highlights and Financial Review Net Profit Attributable to Shareholders RMB 765 million (+25.42 ...